James Deng

Leading product marketing strategy for molecular biology portfolios, I focus on developing and executing comprehensive strategies for new product launches targeted to the biopharma and life sciences sectors. My role encompasses product lifecycle management and customer segmentation, driving market development initiatives and ensuring successful product positioning to maximize market penetration and revenue growth.

Led and drove strategic growth initiatives for the Protein Analysis franchise, focusing on both near-term and long-term objectives. My role encompassed product development, product management, and business development, ensuring sustained growth and innovation. I spearheaded the development and launch of new products, managed the product lifecycle, and identified new market opportunities. Additionally, I fostered strategic partnerships, collaborated with cross-functional teams to drive business success, and managed a team of direct reports and global team members to accomplish these goals.

Managed the global lifecycle and strategy for cell culture, bioprocessing, Alexa Fluor secondary antibody and ELISA portfolios. Led cross-functional teams to bring new products from concept to launch, taking ownership of global pricing, positioning, and stakeholder alignment. Directed the technical content strategy to ensure product documentation and educational resources supported customer needs, while leveraging SEO and digital marketing initiatives to increase web traffic, add-to-cart conversions, and overall revenue growth.

Engaged in a unique NIH-supported fellowship designed to enhance leadership and research skills. Developed teaching and mentoring skills while promoting the advancement of under-represented minorities in science. This role combined hands-on research with impactful educational initiatives, fostering both personal and professional growth. Uncovered the mechanisms of allosteric signaling in a key family of transcription activators, crucial for the expression of virulence factors in bacterial pathogens. Our research aimed to enhance the development of inhibitors for these proteins, potentially leading to new antibacterial agents.